Measuring response to chemotherapy in locally advanced breast cancer: Methodological considerations
Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options, Page: 169-180
2008
- 7Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures7
- Readers7
Book Chapter Description
In this chapter the findings of response-monitoring studies in breast cancer, using [F]2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET), are summarised. These studies indicate that there is a strong relationship between response and decrease in FDG signal even at an early stage of therapy. The review concentrates on methodological aspects of monitoring response with FDG: timing of serial scans, ROI definition approach, method of quantification, pitfalls of FDG and future directions in functional imaging. For the sake of optimal clinical applicability there now is need to standardise methodology. This is necessary to establish firm cut-off values for discriminating responders from non-responders, which in turn will provide a means for optimal treatment for as many patients as possible. © 2008 Springer-Verlag Berlin Heidelberg.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84892212064&origin=inward; http://dx.doi.org/10.1007/978-3-540-36781-9_13; http://link.springer.com/10.1007/978-3-540-36781-9_13; http://link.springer.com/content/pdf/10.1007/978-3-540-36781-9_13.pdf; http://www.springerlink.com/index/10.1007/978-3-540-36781-9_13; http://www.springerlink.com/index/pdf/10.1007/978-3-540-36781-9_13; https://dx.doi.org/10.1007/978-3-540-36781-9_13; https://link.springer.com/chapter/10.1007/978-3-540-36781-9_13
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know